Myriad to Announce Fiscal First-Quarter 2020 Financial Results on November 4, 2019
October 30 2019 - 4:05PM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular
diagnostics and precision medicine, announced that it will hold its
fiscal first-quarter 2020 sales and earnings conference call with
investors and analysts at 4:30 p.m. ET on Monday, November 4,
2019. During the call, Mark C. Capone, president and CEO, and
Bryan Riggsbee, CFO, will provide an overview of Myriad’s financial
performance for the fiscal first-quarter and provide a business
update.
To listen to the earnings call, interested parties
in the United States may dial 800-945-0427 or +1 212-231-2918 for
international callers. All callers will be asked to reference
reservation number 21931991. The conference call also will be
available through a live webcast and a slide presentation
pertaining to the earnings call also will be available under the
investor section of our website at www.myriad.com. A replay
of the call will be available two hours after the end of the call
for seven days and may be accessed by dialing 800-633-8284 within
the United States or +1 402-977-9140 for international callers and
entering reservation number 21931991.
About Myriad GeneticsMyriad Genetics Inc., is a
leading molecular diagnostic and precision medicine company
dedicated to being a trusted advisor transforming patient lives
worldwide with pioneering molecular diagnostics. Myriad
discovers and commercializes molecular diagnostic tests that:
determine the risk of developing disease, accurately diagnose
disease, assess the risk of disease progression, and guide
treatment decisions across six major medical specialties where
molecular diagnostics can significantly improve patient care and
lower healthcare costs. Myriad is focused on five strategic
imperatives: building upon a solid hereditary cancer
foundation, growing new product volume, expanding reimbursement
coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris,
Foresight and Prequel are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G.
Media Contact:Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:Scott Gleason(801)
584-1143sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024